Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05502393 Recruiting - Clinical trials for Advanced Solid Tumors

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

Start date: July 26, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced or Metastatic Solid Tumors.

NCT ID: NCT05502367 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia

Start date: September 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label study to evaluate the safety, tolerability, and efficacy of ABI-2280 in participants with cervical squamous intraepithelial lesions. This study is divided into 2 parts - Part A and Part B. Part A consists of 3 dose escalating cohorts. Part B is a dose expansion cohort. Participants will self-administer ABI-2280.

NCT ID: NCT05501912 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Start date: September 1, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in patients with BRAF V600-Mutant advanced solid tumors. This study consists of two stages: dose escalation and dose expansion. During the dose escalation stage, a classic "3+3" design will be used to guide dose escalation to determine MTD and RP2D. The dose expansion stage will be initiated at the MTD or the optimal dose determined by the Safety Monitoring Committee (SMC ) as a fixed dose level (MTD or the optimal dose needs to be reviewed by the SMC and subjects are safe and tolerable at that dose level).

NCT ID: NCT05501821 Recruiting - Clinical trials for Advanced Solid Tumor Malignancy

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

Start date: August 8, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to assess the safety and efficacy of KBA1412, a patient derived, fully human, monoclonal antibody targeting CD9, in patients with advanced solid malignant tumors

NCT ID: NCT05499715 Not yet recruiting - Clinical trials for Advanced Tumor of Digestive Tract or Urinary System

A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid Tumors

Start date: September 30, 2022
Phase: Phase 1
Study type: Interventional

This is an open-lable, single-arm, dose escalation and dose extension phase I clinical study of ScTIL designed to observe and evaluate the safety, the tolerance, the pharmacokinetic characteristics and the effectiveness of ScTIL in the treatment of advanced malignant solid tumors, in order to provide the basis for the future clinical research to explore the best recommended phase II dose (PR2D) and treatment scheme.

NCT ID: NCT05498519 Recruiting - Clinical trials for Advanced Solid Tumor

A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor

Start date: April 15, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label and multicenter study of SY-4798, a highly specific and potent inhibitor of FGFR4, in patients with advanced solid tumor. This study has two phases: dose-escalation phase and dose-expansion phase.

NCT ID: NCT05498051 Completed - Clinical trials for Colorectal Neoplasms

Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW.

IBIZA-1
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections

NCT ID: NCT05497726 Completed - Clinical trials for Colorectal Neoplasms

Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Intravenous Bevacizumab-800CW

IBIZA-2
Start date: January 27, 2023
Phase: N/A
Study type: Interventional

This prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using intravenous administration.

NCT ID: NCT05496972 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology

Start date: April 21, 2021
Phase:
Study type: Observational

To understand more about the opinions of patients and health providers on the use of telemedicine in radiation oncology.

NCT ID: NCT05496595 Terminated - Clinical trials for Advanced or Metastatic Solid Tumors

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Start date: October 26, 2022
Phase: Phase 1
Study type: Interventional

Study DCBY02-101 is a multicenter, open-label, Phase 1 study to assess the effects of anti-CD93 mAb (DCBY02) as a monotherapy in patients with advanced or metastatic solid tumors.